摘要
目的探究Zn(PMFPCl)2对肝癌Hep G2细胞的抑制作用及其机制。方法 Hep G2细胞分组为对照组及实验组(10、30、70μmol/L)。MTT法检测Zn(PMFPCl)2对肝癌Hep G2细胞增殖的影响,流式细胞仪检测细胞凋亡及细胞周期,倒置显微镜下观察Zn(PMFPCl)2作用后肿瘤细胞的形态学变化,Western blot检测凋亡蛋白p53、p21、caspase-3、bax、bcl-2的表达情况。结果各实验组(10、30、70μmol/L)在24、48、72 h对细胞的抑制率均显著高于对照组(P<0.05)。当Zn(PMFPCl)2浓度70μmol/L,作用72 h时细胞的抑制率最高,达63.29%。各实验组在48 h时的细胞凋亡率显著高于对照组(P<0.05)。Zn(PMFPCl)2使细胞的生长停滞在G1期,阻碍细胞增殖。当Zn(PMFPCl)2作用细胞后贴壁细胞数量减少,细胞皱缩,细胞膜出现突起,细胞变圆、变亮。Western blot法检测p53、p21、caspase-3、bax随配合物浓度的增加而增加,而bcl-2随之减少(P<0.05)。结论 Zn(PMFPCl)2对肝癌Hep G2细胞具有抑制增殖及促进凋亡的作用,其机制与促进p53、p21、caspase-3、bax表达而降低bcl-2表达有关。
Objective To explore the inhibition of Zn(PMFPCl) 2 on HepG2 cells and its mechanism.Methods The HepG2 cells were divided into control group and experimental group of 10, 30 and 70 μmol/L.The cell proliferation was detected by MTT assay, cell apoptosis and cell cycle was analysed by flow cytometry, cellular morphological change was observed with inverted microscope and the expressions of apoptosis-regulated proteins of p53, p21, caspase-3, bax and bcl-2 in HepG2 cells were detected by Western blot.Results The inhibitory rates of experimental groups (10, 30, 70μmol/L) at 24, 48 and 72h were significantly higher than those of control group (P<0.05), and the highest one was 63.29% of 70 μmol/L Zn (PMFPCl)2at 72 h.The apoptosis rates of each experimental group at 48h was significantly higher than that of control group (P<0.05).The cells were induced a remarkable G1 arrest by Zn(PMFPCl) 2 which could inhibit proliferation.The number of adherent cells reduced and cells shrank, convex on cytomembrane surface appeared and the cells changed to round and were brighter.Western blot results showed that the protein levels of p53, p21, caspase-3 and bax increased and bcl-2 decreased with the Zn(PMFPCl)2concentration increasing (P<0.05).Conclusion Zn(PMFPCl)2 could inhibit the proliferation and promote apoptosis of HepG2 cells whose mechanisms are promotation of p53, p21, caspase-3 and bax expressions and inhibition of bcl-2 expression.
出处
《中国生化药物杂志》
CAS
2015年第10期11-14,共4页
Chinese Journal of Biochemical Pharmaceutics
基金
河北省卫生厅科研基金项目(ZL20140116)
吴阶平医学基金会临床科研专项基金(320.6750.14119)
